+30.4%
GSK vs RMBS
+16.3%
+14.1%
-18.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | RMBS | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.9% | +1.3% | -3.3% | -1.9% |
| 7D | -1.8% | -0.3% | -1.5% | -1.8% |
| 30D | -2.2% | -12.2% | +10.0% | -2.3% |
| 3M | -1.8% | -49.5% | +47.7% | -1.4% |
| 6M | -10.6% | -7.1% | -3.5% | -12.2% |
| YTD | +4.4% | -7.0% | +11.4% | +1.8% |
| 1Y | +30.4% | +13.3% | +17.1% | +26.4% |
| All | +30.4% | +16.3% | +14.1% | +26.4% |
Cumulative growth
Daily Returns
Daily percentage return beside RMBS.
Daily Out/Under-Performance
Portfolio return minus RMBS return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × RMBS return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded RMBS wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling